Literature DB >> 16614029

Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.

C H Williams-Gray1, A Goris, T Foltynie, J Brown, M Maranian, A Walton, D A S Compston, S J Sawcer, R A Barker.   

Abstract

The LRRK2 G2019S mutation is the commonest genetic cause of Parkinson's disease (PD) identified to date, although estimates of its prevalence in idiopathic disease vary considerably. Our objectives were to determine G2019S mutation frequency in an unselected, community based cohort of idiopathic PD cases from the UK and to describe phenotypic characteristics among carriers. The mutation was present in two of 519 cases (0.4%) and none of 887 control individuals. The true prevalence of the mutation in idiopathic disease, its penetrance, and the phenotypic heterogeneity of associated cases have important implications for genetic screening in the clinical field.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614029      PMCID: PMC2117467          DOI: 10.1136/jnnp.2005.085019

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  LRRK2 mutations in Parkinson disease.

Authors:  M Farrer; J Stone; I F Mata; S Lincoln; J Kachergus; M Hulihan; K J Strain; D M Maraganore
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

2.  A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.

Authors:  C P Zabetian; A Samii; A D Mosley; J W Roberts; B C Leis; D Yearout; W H Raskind; A Griffith
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

3.  Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation.

Authors:  Hao Deng; Weidong Le; Yi Guo; Christine B Hunter; Wenjie Xie; Joseph Jankovic
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

4.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Authors:  Jennifer Kachergus; Ignacio F Mata; Mary Hulihan; Julie P Taylor; Sarah Lincoln; Jan Aasly; J Mark Gibson; Owen A Ross; Timothy Lynch; Joseph Wiley; Haydeh Payami; John Nutt; Demetrius M Maraganore; Krzysztof Czyzewski; Maria Styczynska; Zbigniew K Wszolek; Matthew J Farrer; Mathias Toft
Journal:  Am J Hum Genet       Date:  2005-02-22       Impact factor: 11.025

5.  The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients.

Authors:  E K Tan; H Shen; L C S Tan; M Farrer; K Yew; E Chua; R D Jamora; K Puvan; K Y Puong; Y Zhao; R Pavanni; M C Wong; Yuen Yih; L Skipper; Jian-Jun Liu
Journal:  Neurosci Lett       Date:  2005-08-26       Impact factor: 3.046

6.  Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Authors:  Jan O Aasly; Mathias Toft; Ignacio Fernandez-Mata; Jennifer Kachergus; Mary Hulihan; Linda R White; Matthew Farrer
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

7.  The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases.

Authors:  Dena Hernandez; Coro Paisan Ruiz; Anthony Crawley; Roneil Malkani; John Werner; Katrina Gwinn-Hardy; Dennis Dickson; Fabienne Wavrant Devrieze; John Hardy; Andrew Singleton
Journal:  Neurosci Lett       Date:  2005-12-09       Impact factor: 3.046

8.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

9.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  12 in total

1.  No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease.

Authors:  Caroline Williams-Gray; An Goris; Thomas Foltynie; Alastair Compston; Stephen Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

Review 2.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 3.  LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.

Authors:  Vincenzo Bonifati
Journal:  Neurochem Res       Date:  2007-04-18       Impact factor: 3.996

Review 4.  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Authors:  Payal N Gandhi; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

5.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Authors:  Caroline H Williams-Gray; An Goris; Misuzu Saiki; Thomas Foltynie; D Alastair S Compston; Stephen J Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

Review 6.  The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.

Authors:  Lucy M Collins; Caroline H Williams-Gray
Journal:  Front Psychiatry       Date:  2016-05-20       Impact factor: 4.157

7.  Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease.

Authors:  Lara Marrone; Christine Bus; David Schöndorf; Julia Catherine Fitzgerald; Manuela Kübler; Benjamin Schmid; Peter Reinhardt; Lydia Reinhardt; Michela Deleidi; Tanya Levin; Andrea Meixner; Barbara Klink; Michael Glatza; Christian Johannes Gloeckner; Thomas Gasser; Jared Sterneckert
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

8.  Age-related cognitive decline in baboons: modeling the prodromal phase of Alzheimer's disease and related dementias.

Authors:  Stephanny Lizarraga; Etienne W Daadi; Gourav Roy-Choudhury; Marcel M Daadi
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

9.  The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation.

Authors:  Azad Kumar; Elisa Greggio; Alexandra Beilina; Alice Kaganovich; Diane Chan; Jean-Marc Taymans; Benjamin Wolozin; Mark R Cookson
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.